Stem cell effort mired in legal bog, global scandal
By Carl T. Hall,
San Francisco Chronicle
| 01. 22. 2006
California's Proposition 71 program was intended to create a $3 billion West Coast counterpart to the National Institutes of Health empowered to go where the NIH could not: full steam into the new field of biomedical research centered on human embryonic stem cells.
Instead, the program has gotten stuck in a seemingly endless legal morass. Although state officials say they are optimistic about their chances in court, it's expected that the program will take at least 15 more months to slog through appeals and start issuing the first major grants. Meanwhile, revelations of faked cloning research in South Korea have set back the scientific agenda and scandalized the entire stem cell field.
Rather than ramping up a bold, $350 million annual grant-making operation, the California Institute for Regenerative Medicine appears to be entering a new era of declining expectations one year into its intended 10-year lifespan.
see moreUniversities have had to put construction plans on extended hold because of Prop. 71's slow start, while researchers seek other sources of grants to tide them over. At the same time, the nation's main...
Related Articles
By Emma McDonald Kennedy
| 10.29.2026
At the beginning of Nathan Fielder and Lance Oppenheim’s blockbuster documentary You Can See Everything, Billy Evans (partner of Theranos founder and convicted fraudster Elizabeth Holmes), says that they decided to do the film for one purpose: “radical transparency.” As they work on “Theranos 2.0,” Evans and Holmes want to show the public that she has been misunderstood –– painted as a liar and a fraud in the public imagination (and the courts) despite, as she claims in the...
By Charles Schmidt, Undark | 09.25.2026
In 2010, scientists at the University of Tokyo and other institutions reported a startling achievement: They had successfully grown a pancreas made almost entirely of rat cells within the bodies of mice. The research was directed by Hiromitsu Nakauchi, a...
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...